Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Ltd (GDTC) is a pioneering biopharmaceutical company developing innovative cell-based immunotherapies targeting cancer treatment. Specializing in off-the-shelf γδ T cell and NK cell therapies, the company bridges cutting-edge research with clinical applications through strategic collaborations and patented technologies.
This news hub provides investors and industry professionals with timely updates on CytoMed's advancements in oncology therapeutics. Access press releases detailing clinical trial progress, regulatory milestones, and partnership announcements that demonstrate the company's scientific rigor and market positioning.
Key updates include developments in allogeneic cell therapies, intellectual property achievements, and preclinical research breakthroughs. The curated collection serves as a centralized resource for tracking CytoMed's progress in addressing solid tumor treatment challenges and expanding its therapeutic pipeline.
Bookmark this page for direct access to verified updates on CytoMed's contributions to cancer immunotherapy. Regularly updated content ensures stakeholders stay informed about the company's role in advancing accessible, next-generation cellular treatments.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking license and assets from Cellsafe International for approximately US$490,000. The acquisition includes cryopreservation equipment with over 12,000 cord blood units and two freehold properties. This move strengthens CytoMed's position in allogeneic gamma delta (γδ) T cell technology for cancer treatment.
Additionally, CytoMed has been granted a new patent in Malaysia for its iPSC-derived hybrid γδ NKT cells technology, expanding its tumor-targeting therapy patent portfolio. The company aims to develop cytotoxic γδ T cells from three sources: adult peripheral blood mononuclear cells, induced Pluripotent Stem Cells, and cord blood.
CytoMed plans to repurpose cord blood units for a wider range of therapies, including solid cancer treatment. The company is currently conducting the ANGELICA Trial, a phase 1 clinical trial in Singapore focused on CAR-T therapy.
FAQ
What is the current stock price of CytoMed Therapeutics (GDTC)?
What is the market cap of CytoMed Therapeutics (GDTC)?
